SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
64
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ideanomics, Inc. of Class Action Lawsuit and Upcoming Deadline – IDEX

NEW YORK, Aug. 15, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ideanomics, Inc. (“Ideanomics” or the “Company”)(NASDAQ: IDEX) and certain of its officers.   The class action, filed in the United States District Court for the Southern District of New York, and indexed under 20-cv-05203, is on behalf of all investors who purchased or otherwise acquired Ideanomics, Inc. (“Ideanomics” or the “Company”) securities between March 20, 2020, and June 25, 2020, inclusive (the “Class Period”).  This action is brought on behalf of the Class for violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”), 15 U.S.C. §§ 78j(b) and 78t(a) and Rule 10b-5 promulgated thereunder by the SEC, 17 C.F.R. § 240.10b-5.

If you are a shareholder who purchased Ideanomics securities during the Class Period, you have until August 27, 2020, to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com .   To discuss this action, contact Robert S. Willoughby at newaction@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

[Click here for information about joining the class action]

Ideanomics purports to be a global company focused on facilitating the adoption of commercial electric vehicles and developing next generation financial services and Fintech products.  Ideanomics common stock trades on the NASDAQ stock exchange under the ticker “IDEX.”  The Company is headquartered in New York, New York, and maintains offices in Beijing and Qingdao, China.

In recent press releases, Ideanomics has lauded its “one million square foot EV expo center in Qingdao, Shandong Province,” in China, also known as the Company’s Mobile Energy Global (MEG) Division, or the “MEG Center.”  According to Ideanomics, the MEG Center is “the largest auto trading market in Qingdao,” China.

Throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Ideanomics’ MEG Center in Qingdao was not “a one million square foot EV expo center”; (ii) the Company had been using doctored or altered photographs of the purported MEG Center in Qingdao; (iii) the Company’s electric vehicle business in China was not performing nearly as strong as Ideanomics had represented; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

On June 25, 2020, analyst Hindenburg Research (“Hindenburg”) issued a series of tweets in which it called Ideanomics “an egregious & obvious fraud.”  Hindenburg asserted that it found evidence that Ideanomics had doctored photos for use in its press releases to suggest that the Company owns or operates a vehicle sales center in Qingdao, China, when it in fact does not.  Hindenburg further asserted that it had an investigator go to Ideanomics’ purported MEG Center in Qingdao, China, where the investigator was unable to find any trace of Ideanomics or its purported MEG Center.

Also on June 25, 2020, analyst J Capital Research issued a report on Ideanomics entitled “Champion of Promotes.”  J Capital wrote, in part, that “Ideanomics . . . is a zero. The company changes its name and promotional story so frequently that it’s hard to keep up. One thing remains a constant, despite all the press releases, buzzwords and hype: shareholders get wiped out.”  J Capital continued, in a tweet, that “[w]e called all the ‘buyers’ named in [Ideanomics’] press releases this month. Not a single one had made a purchase. One of them thanked us for alerting them to ‘fake news.’”

On this news, Ideanomics’ stock price fell from its June 24, 2020 closing price of $3.09 per share to a June 25, 2020 closing price of $2.44 per share, a one day drop of $0.65 per share, or approximately 21%.

Then on June 26, 2020, Ideanomics issued a press release in which it sought to “clarify the status” of its purported EV hub in Qingdao, China.  In this release, Ideanomics walked back certain of its prior statements regarding the MEG Center in Qingdao, stating that it was launching three phases of its MEG Center that will eventually total one million square feet.  The first phase, according to Ideanomics, occupies only 215,000 square feet.

The stock price continued to plummet on June 26, 2020, dropping to a close of $1.46 per share.  This represents a two day drop of approximately 53%.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT: Robert S. Willoughby Pomerantz LLP rswilloughby@pomlaw.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 5

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 6

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 3

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 14

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading

Top 5 Most Recently Viewed Articles

PARRIS Law Firm Triumphs in Landmark Billing Case Against Edison

Updated Category News Views 258

PARRIS Law Firm Achieves Major Victory in Consumer Lawsuit The PARRIS Law Firm has recently celebrated a significant win for consumers in a landmark lawsuit against Southern California Edison Company. This case, referencing the Wellman v. Southern California Edison Company, has captured media attention, notably from The Daily Journal, showcasing the firm’s commitment to...

Continue Reading
Intercont (Cayman) Limited's Growth: Exploring Recent Financials

Updated Category News Views 112

Intercont (Cayman) Limited Unveils Financial Results Intercont (Cayman) Limited (NASDAQ: NCT), a prominent leader in the global shipping industry, has shared its financial results for the first half of the fiscal year. The company, renowned for its innovative approach to seaborne pulping operations, reported notable advancements in its financial performance, reflecting...

Continue Reading
What to Expect from Quanex Building Products' Earnings Report

Updated Category News Views 107

Understanding the Upcoming Earnings of Quanex Building Products Quanex Building Products (NASDAQ: NX) is gearing up to announce its quarterly earnings. This moment has been highly anticipated by investors eager to gain insights into the company's financial health. While specific dates are typically essential to focus on, the critical takeaway for investors is the...

Continue Reading
ZERO Fresh Start: RAVEN2's New Era Begins Sept 15

Updated Category News Views 18

What's the Big Deal with ZERO? Alright, so here we go, folks—Netmarble's strapping in with their latest server for RAVEN2, and it's called ZERO. Ever heard of fresh starts? ZERO is exactly that. This isn't your usual server shuffle. Lads and ladies who've felt the grind’ll tell you, ZERO's introducing a slew of changes you might want to sit up for. Pre-registration's...

Continue Reading
Innovative Cancer Treatments: CMU and Healthcare System Lead the Way

Updated Category News Views 266

Revolutionizing Cancer Treatment China Medical University (CMU) and Healthcare System are making significant strides in the field of cancer treatment, notably through AI-driven drug discovery and innovative therapies. At a recent healthcare exposition, these organizations showcased their leading-edge advancements, establishing themselves as pioneers in healthcare...

Continue Reading